The effectiveness of clopidogrel in the prevention of thrombotic complications in patients with acute coronary syndrome and genetic factors

Cover Page

Cite item

Full Text

Abstract

This review article presents the current views on genotyping during administration of clopidogrel - an antiplatelet drug from the class of thienopyridines, for patients with acute coronary syndrome. Highlighted were the data on genetic disorders affecting the absorption and metabolism of clopidogrel. The gene ABCB1 (MDR1) encodes the intestinal transporter P-glycoprotein. The variability of this gene may affect the bioavailability of clopidogrel. However, data on the relationship between C3435T polymorphism of ABCB1 gene and the expression of P-glycoprotein still remain controversial. Differences in the effects of C3435T may reflect the differences in the frequency of ABCB1 polymorphism among ethnic groups and the complex of effects of different polymorphisms in the same gene within a haplotype, or confounding factors of the environment. The most important role in the metabolism of clopidogrel is played by cytochrome P-450 (iso-enzyme CYP2C19). Several large studies have confirmed the prognostic significance of CYP2C19 polymorphism in patients receiving clopidogrel. In a recent meta-analysis of nine pharmacogenetic studies of clopidogrel, which included 9685 patients with acute coronary syndrome, revealed was a significant association between the homozygous and heterozygous alleles with reduced CYP2C19 function and an increased risk of death due to cardiovascular disease, myocardial infarction or stroke. Two large randomized studies of CYP2C19 genotyping did not reveal any relationship between its variants and the occurrence of cardiovascular events in patients with acute coronary syndrome or atrial fibrillation. Thus, in genetic studies of the antiplatelet effectiveness of clopidogrel, there are many uncertainties; domestic data on this subject is extremely scarce.

About the authors

A S Galyavich

Kazan State Medical University, Kazan, Russia

Email: agalyavich@mail.ru

D D Valeeva

Kazan State Medical University, Kazan, Russia

References

  1. Angiolillo D., Fernández Ortiz A., Bernardo E. et al. Variability in individual responsiveness to clopidogrel. Clinical implications, management, and future perspectives // J. Am. Coll. Cardiol. - 2007. - Vol. 49. - P. 1505-1516.
  2. Angiolillo D., Bates E. Platelet inhibitor therapy: current perspectives and emerging novel agents: introduction // Am. Heart J. - 2008. - Vol. 156. - P. 1-2.
  3. Angiolillo D., Bernardo E., Trabetti E. et al. Role of the C1236T rs1128503) polymorphism of the MDR-1 gene on clopidogrel responsiveness (abstr.) // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 301.
  4. Bertrand M., Rupprecht H., Urban P., Gershlick A. CLASSICS Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) // Circulation. - 2000. - Vol. 102. - P. 624-629.
  5. Brandt J., Close S., Iturria S. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel // J. Thromb. Haemost. - 2007. - Vol. 5. - P. 2429-2436.
  6. Collet J., Hulot J., Pena A. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study // Lancet. - 2009. - Vol. 373. - P. 309-317.
  7. Desta Z., Zhao X., Shin J., Flockhart D. Clinical significance of the cytochrome P450 2C19 genetic polymorphism // Clin. Pharmacokinet. - 2002. - Vol. 41. - P. 913-958.
  8. Farid N., Payne C., Small D. et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently // Clin. Pharmacol. Ther. - 2007. - Vol. 81. - P. 735-741.
  9. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug // URL: http://www.fda.gov/drugs/ drugsafety/PostmarketDrugSafety InformationforPatientsandProviders/ ucm203888.htm.
  10. Geiger J., Honig-Liedl P., Schanzenbacher P., Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors // Eur. J. Pharmacol. - 1998. - Vol. 351. - P. 235-246.
  11. Geiger J., Brich J., Honig-Liedl P. et al. Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel // Arterioscler. Thromb. Vasc. Biol. - 1999. - Vol. 19. - P. 2007-2011.
  12. Gerloff T., Schaefer M., Johne A. et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males // Br. J. Clin. Pharmacol. - 2002. - Vol. 54. - P. 610-616.
  13. Grines C., Bonow R., Casey Jr.D. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians // J. Am. Coll. Cardiol. - 2007. - Vol. 49. - P. 734-739.
  14. Hoffmeyer S., Burk O., von Richter O. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo // Proc. Natl. Acad. Sci. USA. - 2000. - Vol. 97. - P. 3473-3478.
  15. Holmes D.Jr, Dehmer G., Kaul S. et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA «boxed warning»: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons // J. Am. Coll. Cardiol. - 2010. - Vol. 56. - P. 321-341.
  16. Huber K. Genetic variability in response to clopidogrel therapy: clinical implications // Eur. Heart J. - 2010. - Vol. 31. - P. 2974-2976.
  17. Hulot J.-S., Bura A., Villard E. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects // Blood. - 2006. - Vol. 108. - P. 2244-2247.
  18. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2C19 allele nomenclature // URL: http://www.cypalleles. ki.se/cyp2c19.htm (дата обращения - март 2010).
  19. Kazui M., Ishizuka T., Yamamura N. et al. Mechanism for production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist [abstract] // Thromb. Haemostasis. - 2001. - Vol. 85. - P. 1916.
  20. Kazui М., Nishiya Y., Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite // Drug. Metab. Dispos. - 2010. - Vol. 38. - P. 92-99.
  21. King S. 3rd., Smith Jr.S., Hirshfeld Jr.J. et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 172-209.
  22. Kroetz D., Pauli-Magnus C., Hodges L. et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene // Pharmacogenetics. - 2003. - Vol. 13. - P. 701.
  23. Lee J., Park S., Shin D. et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans // Am. J. Cardiol. - 2009. - Vol. 104. - P. 46-51.
  24. Leschziner G., Andrew T., Pirmohamed M., Johnson M. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research // Pharmacogenomics J. - 2007. - Vol. 7. - P. 154-179.
  25. Man M., Farmen M., Dumaual C. et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East asian subpopulations with comparison to Caucasians and Africans // J. Clin. Pharmacol. - 2010. - Vol. 50. - P. 929-940.
  26. Marzolini C., Paus E., Buclin T., Kim R. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance // Clin. Pharmacol. Ther. - 2004. - Vol. 75. - P. 13-33.
  27. Mehta S., Yusuf S., Peters R. et al. Clopidogrel in unstable angina to prevent recurrent events trial CURE investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study // Lancet. - 2001. - Vol. 358. - P. 527-533.
  28. Mega J., Close S., Wiviott S. et al. Cytochrome p-450 polymorphisms, response to clopidogrel // N. Engl. J. Med. - 2009. - Vol. 360. - P. 354-362.
  29. Mega J., Close S., Wiviott S. et al. Cytochrome P450 genetic polymorphisms the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes // Circulation. - 2009. - Vol. 119. - P. 2553-2560.
  30. Mega J., Simon T., Collet J.-P. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis // JAMA. - 2010. - Vol. 304. - P. 1821-1830.
  31. Mega J., Close S., Wiviott S. et al. ABCB1 genetic variants, pharmacodynamics respons and cardiovascular outcomes following treatment with clopidogrel and prasugrel // J. Am. Coll. Cardiol. - 2010. - Vol. 55. - P. 113.
  32. Moriya Y., Nakamura T., Horinouchi M. et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects // Biol. Pharm. Bull. - 2002. - Vol. 25. - P. 1356-1359.
  33. Nakamura T., Sakaeda T., Horinouchi M. et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects // Clin. Pharmacol. Ther. - 2002. - Vol. 71. - P. 297-303.
  34. Pereillo J.-M., Maftouh M., Andrieu A. et al. Structure and Stereochemistry of the Active Metabolite of Clopidogrel // Drug Metab. Dispos. - 2002. - Vol. 30. - P. 1288-1295.
  35. Rehmel J., Eckstein J., Farid N. et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 // Drug Metab. Dispos. - 2006. - Vol. 34. - P. 600-607.
  36. Savi P., Herbert J., Pflieger A. et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel // Biochem. Pharmacol. - 1992. - Vol. 44. - P. 527-532.
  37. Savi P., Pereillo J., Uzabiaga M. et al. Identification and biological activity of the active metabolite of clopidogrel // Thromb. Haemost. - 2000. - Vol. 84. - P. 891-896.
  38. Savi P., Herbert J. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis // Semin. Thromb. Hemost. - 2005. - Vol. 31. - P. 174-183.
  39. Schaeffeler E., Eichelbaum M., Brinkmann U. et al. Frequency of C3435T polymorphism of MDR1 gene in African people // Lancet. - 2001. - Vol. 358. - P. 383-384.
  40. Shuldiner A., Bilden K., Gandhi A. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy // JAMA. - 2009. - Vol. 302. - P. 849-857.
  41. Simon T., Verstuyft C., Mary-Krause M. et al. Genetic determinants of response to clopidogrel and cardiovascular events // N. Engl. J. Med. - 2009. - Vol. 360. - P. 363-375.
  42. Taubert D., von Beckerath N., Grimberg G. et al. Impact of P-glycoprotein on clopidogrel absorption // Clin. Pharmacol. Ther. - 2006. - Vol. 80. - P. 486-501.
  43. Wallentin L., James S., Storey R. et al. For the PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial // Lancet. - 2010. - Vol. 376. - P. 1320-1328.
  44. Yusuf S., Zhao F., Mehta S. et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation // N. Engl. J. Med. - 2001. - Vol. 345. - P. 494-502.

© 2012 Galyavich A.S., Valeeva D.D.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies